WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004099244) IMMUNOGENIC HUMAN TNF ALPHA ANALOGUES WITH REDUCED CYTOTOXICITY AND METHODS OF THEIR PREPARATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/099244    International Application No.:    PCT/DK2004/000329
Publication Date: 18.11.2004 International Filing Date: 06.05.2004
Chapter 2 Demand Filed:    08.03.2005    
IPC:
A61K 38/00 (2006.01), A61K 39/00 (2006.01), C07K 14/525 (2006.01)
Applicants: PHARMEXA A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK) (For All Designated States Except US).
BRATT, Tomas [SE/DK]; (DK) (For US Only).
KLYSNER, Steen [DK/DK]; (DK) (For US Only).
NIELSEN, Finn [DK/DK]; (DK) (For US Only).
MOURITSEN, Søren [DK/DK]; (DK) (For US Only).
VOLDBORG, Bjørn [DK/DK]; (DK) (For US Only)
Inventors: BRATT, Tomas; (DK).
KLYSNER, Steen; (DK).
NIELSEN, Finn; (DK).
MOURITSEN, Søren; (DK).
VOLDBORG, Bjørn; (DK)
Agent: INSPICOS A/S; Bøge Allé 5, P.O. Box 45, DK-2970 Hørsholm (DK)
Priority Data:
PA 2003 00701 09.05.2003 DK
60/469,491 09.05.2003 US
Title (EN) IMMUNOGENIC HUMAN TNF ALPHA ANALOGUES WITH REDUCED CYTOTOXICITY AND METHODS OF THEIR PREPARATION
(FR) TNF DETOXIFIE ET TECHNIQUE DE PREPARATION
Abstract: front page image
(EN)The present invention provides for an immunogenic analogue of a human TNF&agr; protein, wherein said analogue comprises an immunogenized monomeric TNF&agr; polypeptide or TNF&agr; di- or trimer, and wherein the analogue further comprises a toxicity reducing or abolishing mutation selected from the group consisting of Y87S, D143N or A145R, the amino acid numbering setting out from the N-terminal valine in human TNF&agr;. The invention also provides for a nucleic acid fragment encoding the analogue as well as to vectors and transformed cells useful in the preparation of the analogue. Also disclosed are methods of down-regulating TNF&agr; in a subject in need thereof.
(FR)La présente invention concerne un analogue immunogénique de protéine TNF a humaine, cet analogue comprenant un polypeptide TNF a ou un dimère ou trimère TNFa, cet analogue comprenant aussi une mutation réduisant ou supprimant la toxicité sélectionnée dans le groupe constitué de Y87S, de D143N ou de A145R, le nombre d'acides aminés étant fixé à partir de valine N-terminal dans le TNF a humain. Cette invention concerne aussi un fragment d'acide nucléique codant pour l'analogue ainsi que des vecteurs et des cellules transformées qui conviennent pour la préparation de cet analogue. Cette invention concerne aussi des techniques de régulation vers le bas du TNFa chez un sujet dont l'état de santé nécessite cette technique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)